SCHEMBL2853759

SCHEMBL2853759

COc1cccc(OC(=O)Cl)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.55
CES1 P23141 1/20 0.55
LMNA P02545 1/20 0.53
PARP1 P09874 1/20 0.52
ESR1 P03372 1/20 0.51
ESR2 Q92731 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
PRSS1 P07477 1/20 0.49
ACR P10323 1/20 0.49
BCHE P06276 1/20 0.49
KDM4E B2RXH2 1/20 0.47
POLB P06746 1/20 0.47
ACHE P22303 1/20 0.47
MTNR1A P48039 2/20 0.46
MTNR1B P49286 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
ENPP2 Q13822 1/20 0.46
MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2489203 0.89 KMT2A (0.60) CES2CES1LMNAMEN1KMT2A
SCHEMBL13719843 0.84 LMNA (0.63) LMNAMEN1KMT2AKDM4EACHE
SCHEMBL30463307 0.83 CES2 (0.59) CES2CES1LMNAPARP1ESR1
SCHEMBL8048513 0.83 CES2 (0.59) CES2CES1LMNAPARP1ESR1
SCHEMBL9671480 0.82 CES2 (0.57) CES2CES1LMNAPARP1ESR1
SCHEMBL5700480 0.82 CES2 (0.57) CES2CES1LMNAPARP1ESR1
SCHEMBL16520280 0.82 KMT2A (0.52) CES2CES1LMNAMEN1KMT2A
SCHEMBL9671485 0.82 LMNA (0.59) CES2CES1LMNAPARP1ESR1
SCHEMBL361383 0.82 LMNA (0.66) CES2CES1LMNAPARP1ESR1
SCHEMBL3955745 0.80 MEN1 (0.80) CES2CES1LMNAPARP1ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6015656-A TABULAR SILICA DISPERSION OBTAINED BY MIXING TABULAR SILICA, GELATIN, CYCLODEXTRIN, COMPOUND CAPABLE OF CROSSLINKING GELATIN KONICA CORPORATION (JP) 2000-01-18 US claimed
EP-2995617-B1 BENZOISOTHIAZOLE COMPOUNDS AND USE IN PREPARATION OF ANTIPSYCHOTIC DRUGS SHANGHAI INST PHARMACEUTICAL IND (CN) 2018-01-31 EP disclosed
US-9550741-B2 Benzoisothiazole compounds and methods of treating schizophrenia SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2017-01-24 US disclosed
US-20160096811-A1 BENZOISOTHIAZOLE COMPOUNDS AND USE IN PREPARATION OF ANTIPSYCHOTIC DRUGS SHANAGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) 2016-04-07 US disclosed
CN-105431422-A Isoindoline or isoquinoline compounds, process for their preparation and pharmaceutical compositions containing them SERVIER LAB 2016-03-23 CN disclosed
EP-2995617-A1 BENZOISOTHIAZOLE COMPOUNDS AND USE IN PREPARATION OF ANTIPSYCHOTIC DRUGS Shanghai Institute of Pharmaceutical Industry (CN) 2016-03-16 EP disclosed
EP-1809653-B1 SUBSTITUTED NONADEPSIPEPTIDES AICURIS GMBH & CO KG (DE) 2010-01-20 EP disclosed
US-7579479-B2 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-25 US disclosed
EP-1218361-B1 OXA- AND THIAZOLE DERIVATIVES USEFUL AS ANTIDIABETIC AND ANTIOBESITY AGENTS BRISTOL MYERS SQUIBB CO (US) 2009-01-07 EP disclosed
EP-1939188-A1 Oxa-and thiazole derivatives useful as antidiabetic and antiobesity agents Bristol-Myers Squibb Company (US) 2008-07-02 EP disclosed
US-5486514-A GASTRIN, CHOLECYSTOKININ RECEPTOR ANTAGONISTS GLAXO SPA (IT) 1996-01-23 US disclosed
EP-0648740-A1 AMINO ACID AMIDE DERIVATIVE, AGROHORTICULTURAL BACTERICIDE, AND PRODUCTION PROCESS KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) 1995-04-19 EP disclosed
EP-0444325-B1 Modified dextran binder for use in thermal dye transfer AGFA GEVAERT NV (BE) 1994-12-07 EP disclosed
EP-0623118-A1 CARBAMATE DERIVATIVES AND THEIR USE IN MEDICINE GLAXO S.p.A. (IT) 1994-11-09 EP disclosed
WO-1993014075-A1 CARBAMATE DERIVATIVES AND THEIR USE IN MEDICINE GLAXO SPA (IT) 1993-07-22 WO disclosed
US-5151405-A Multilayer element of a support and a modified dextran binder AGFA-GEVAERT, N.V. (BE) 1992-09-29 US disclosed
EP-0444325-A1 Modified dextran binder for use in thermal dye transfer AGFA-GEVAERT N.V. (BE) 1991-09-04 EP disclosed
EP-0275583-B1 PHOTOGRAPHIC PROTEINACEOUS LAYERS COMPRISING DEXTRAN DERIVATIVES AGFA-GEVAERT N.V. (BE) 1991-03-06 EP disclosed
US-4879209-A CHLOROFORMATE REACTION PRODUCT FOR HARDENING AGFA-GEVAERT, N.V. (BE) 1989-11-07 US disclosed
EP-0275583-A2 Photographic proteinaceous layers comprising dextran derivatives AGFA-GEVAERT N.V. (BE) 1988-07-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160096811-A1 BENZOISOTHIAZOLE COMPOUNDS AND USE IN PREPARATION OF ANTIPSYCHOTIC DRUGS HTR3A, SLC6A3, HTR5A CES2 4045/4885CES1 4053/4885LMNA 3956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.